Celltrion, Inc. (KRX: 068270)
South Korea
· Delayed Price · Currency is KRW 180,900
+600 (0.33%)
Jan 3, 2025, 3:30 PM KST
Celltrion Revenue
Celltrion had revenue of 881.93B KRW in the quarter ending September 30, 2024, with 31.18% growth. This brings the company's revenue in the last twelve months to 2.88T, up 24.81% year-over-year. In the year 2023, Celltrion had annual revenue of 2.18T, down -4.71%.
Revenue (ttm)
2,876.25B
Revenue Growth
+24.81%
P/S Ratio
12.58
Revenue / Employee
1.20B
Employees
2,391
Market Cap
39.16T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2,176.43B | -107.54B | -4.71% |
| Dec 31, 2022 | 2,283.97B | 390.57B | 20.63% |
| Dec 31, 2021 | 1,893.40B | 44.29B | 2.39% |
| Dec 31, 2020 | 1,849.12B | 720.66B | 63.86% |
| Dec 31, 2019 | 1,128.46B | 146.38B | 14.91% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics Co.,Ltd. | 4,364.39B |
| Yuhan | 2,008.84B |
| SK Biopharmaceuticals | 511.33B |
| SK bioscience Co.,Ltd. | 201.30B |
| Hanmi Pharm. | 1,566.25B |
| Hanmi Science | 1,283.65B |
| GC Biopharma | 1,643.98B |
| Hanall Biopharma | 134.24B |
Celltrion News
- 15 days ago - FDA approves Celltrion's biosimilar of J&J's Stelara - Seeking Alpha
- 24 days ago - Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada - Financial Post